| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,188,470 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,464 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,188,470 |
|
|
| Total
Value |
$52,464 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-05-14 |
3,246,424 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
152 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-28 |
4 |
B |
$11.82 |
$3,546 |
D/D |
300 |
2,964,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-29 |
4 |
B |
$11.62 |
$42,994 |
D/D |
3,700 |
2,968,314 |
3.23 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2022-06-30 |
4 |
S |
$6.53 |
$261,104 |
D/D |
(40,000) |
142,436 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-08-11 |
4 |
B |
$8.40 |
$165,220 |
D/D |
19,669 |
2,987,983 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-08-18 |
4 |
B |
$8.58 |
$123,775 |
D/D |
14,426 |
3,002,409 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-08-19 |
4 |
B |
$8.99 |
$44,950 |
D/D |
5,000 |
3,007,409 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-08-23 |
4 |
B |
$9.00 |
$4,500 |
D/D |
500 |
3,007,909 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-08-29 |
4 |
B |
$9.07 |
$9,070 |
D/D |
1,000 |
3,008,909 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-01 |
4 |
B |
$8.11 |
$4,055 |
D/D |
500 |
3,009,409 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-02 |
4 |
B |
$8.37 |
$10,044 |
D/D |
1,200 |
3,010,609 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-23 |
4 |
B |
$7.93 |
$7,930 |
D/D |
1,000 |
3,011,609 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-26 |
4 |
B |
$7.69 |
$3,845 |
D/D |
500 |
3,012,109 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-28 |
4 |
B |
$7.23 |
$3,615 |
D/D |
500 |
3,012,609 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-09-30 |
4 |
B |
$7.46 |
$3,730 |
D/D |
500 |
3,013,109 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-10 |
4 |
B |
$7.07 |
$7,070 |
D/D |
1,000 |
3,014,109 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-17 |
4 |
B |
$7.24 |
$1,810 |
D/D |
250 |
3,014,359 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-18 |
4 |
B |
$7.23 |
$3,615 |
D/D |
500 |
3,014,859 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-25 |
4 |
B |
$7.38 |
$1,107 |
D/D |
150 |
3,015,009 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-28 |
4 |
B |
$7.40 |
$1,110 |
D/D |
150 |
3,015,159 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-29 |
4 |
B |
$7.45 |
$1,118 |
D/D |
150 |
3,015,309 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-30 |
4 |
B |
$7.45 |
$1,118 |
D/D |
150 |
3,015,459 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
210,000 |
3,225,459 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-03-14 |
4 |
B |
$10.85 |
$18,228 |
D/D |
1,680 |
3,227,139 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-03-15 |
4 |
B |
$10.91 |
$5,237 |
D/D |
480 |
3,227,619 |
3.15 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2023-03-20 |
4 |
B |
$6.48 |
$14,904 |
D/D |
2,300 |
144,736 |
2.39 |
- |
|
152 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
